Clinical Study of Esaxerenone in Hypertension with Heart Failure (Switch Study from Eplerenone)

Clinical Study of Esaxerenone in Hypertension with Heart Failure - Clinical Study of Esaxerenone in Hypertension with Heart Failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037124

Enrollment

150

Registered

2019-06-20

Start date

2019-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with moderate chronic kidney disease

Interventions

Esaxerenone 2.5mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertension with heart failure Patients taking eplerenone orally Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: eGFR<30 Patients from whom informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
Blood pressure	—

Secondary

Measure	Time frame
1) sCr, eGFR 2) osm, cystitin C, ox-LDL, renin, angiotensin-II, aldosterone, cortisol, Na, K, Cl 3) Urine (albumin, Na, K, Cl, osm, IV-FABP) 4) ANP, BNP	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026